Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer

Sponsor
Medical Research Council (Other)
Overall Status
Completed
CT.gov ID
NCT00003175
Collaborator
(none)
45
62
135
0.7
0

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of fluorouracil given as a continuous infusion in treating patients with recurrent or metastatic bladder cancer.

Detailed Description

OBJECTIVES: I. Determine the response rate and toxic effects of continuous fluorouracil in patients with recurrent locally advanced or metastatic transitional cell urinary tract carcinoma. II. Determine the feasibility of this treatment in this patient population.

OUTLINE: Patients receive continuous intravenous fluorouracil by a Baxter Infusor for 24 weeks. Patients are evaluated for complete and partial response at 8, 16, and 24 weeks after the start of intravenous fluorouracil. Patients experiencing disease progression or unacceptable toxic effects are removed from the study. Patients are followed monthly for 6 months post treatment.

PROJECTED ACCRUAL: A maximum of 45 patients will be accrued.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
45 participants
Primary Purpose:
Treatment
Official Title:
A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract
Study Start Date :
Dec 1, 1997
Actual Study Completion Date :
Mar 1, 2009

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    DISEASE CHARACTERISTICS: Histologically proven recurrent locally advanced or metastatic transitional cell urinary tract carcinoma that has been previously untreated with systemic chemotherapy Pelvic relapse after radiotherapy or surgery No relapse solely within a previously irradiated field Nodal or metastatic disease Lesions within the abdomen or pelvis must be assessed using CT scanning At least one site of disease must be previously unirradiated and assessable for response Bone metastases cannot be used as an indicator lesion Measurable disease

    PATIENT CHARACTERISTICS: Age: Not specified Performance Status: Not specified Life Expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Not specified Renal: Glomerular filtration rate at least 50 mL/min Creatinine clearance at least 25 mL/min

    PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Porto Alegre Hospital Porto Alegre Rio Grande do Sul Brazil 90035--003
    2 Cancer Care Ontario-London Regional Cancer Centre London Ontario Canada N6A 4L6
    3 Mount Sinai Hospital - Toronto Toronto Ontario Canada M5G 1X5
    4 Princess Margaret Hospital Toronto Ontario Canada M5G 2M9
    5 Hopital Sainte Justine Montreal Quebec Canada H3T 1C5
    6 Maria Hospital Helsinki Finland FIN-0-0180
    7 Antoni van Leeuwenhoekhuis Amsterdam Netherlands 1066 CX
    8 Christchurch Hospital Christchurch New Zealand 1
    9 Norwegian Radium Hospital Oslo Norway N-0310
    10 Groote Schuur Hospital, Cape Town Cape Town South Africa 7925
    11 Royal United Hospital Bath England United Kingdom BA1 3NG
    12 University Birmingham Birmingham England United Kingdom B15 2TT
    13 Children's Hospital - Birmingham UK Birmingham England United Kingdom B16 8ET
    14 Bradford Hospitals NHS Trust Bradford England United Kingdom BD9 6RJ
    15 Royal Sussex County Hospital Brighton England United Kingdom BN2 5BE
    16 Bristol Royal Hospital for Sick Children Bristol England United Kingdom BS2 8BJ
    17 Bristol Oncology Centre Bristol England United Kingdom BS2 8ED
    18 Addenbrooke's NHS Trust Cambridge England United Kingdom CB2 2QQ
    19 Kent and Canterbury Hospital Canterbury England United Kingdom CT2 7NR
    20 Walsgrave Hospital Coventry England United Kingdom CV2 2DX
    21 Derbyshire Royal Infirmary Derby England United Kingdom DE1 2QY
    22 Derbyshire Children's Hospital Derby England United Kingdom DE1 3BA
    23 Royal Devon and Exeter Hospital Exeter England United Kingdom EX2 5DW
    24 Gloucester Royal NHS Trust - Glouchester Royal Hospital Gloucester England United Kingdom GL1 3NN
    25 Royal Surrey County Hospital Guildford England United Kingdom GU2 5XX
    26 Royal Free Hospital Hampstead, London England United Kingdom NW3 2QG
    27 Huddersfield Royal Infirmary Huddersfield, West Yorks England United Kingdom HD3 3EA
    28 Cookridge Hospital Leeds England United Kingdom LS16 6QB
    29 St. James's Hospital Leeds England United Kingdom LS9 7TF
    30 University Hospitals of Leicester Leicester England United Kingdom LE1 5WW
    31 St. Bartholomew's Hospital London England United Kingdom EC1A 7BE
    32 Guy's, King's and St. Thomas' Hospitals Trust London England United Kingdom SE1 7EH
    33 Westminster Hospital London England United Kingdom SW1P 2AP
    34 Middlesex Hospital- Meyerstein Institute London England United Kingdom W1N 8AA
    35 University College Hospital London England United Kingdom WC1E 6AU
    36 Manchester Children's Hospitals (NHS Trust) Manchester England United Kingdom M27 SHA
    37 Clatterbridge Centre for Oncology NHS Trust Merseyside England United Kingdom L63 4JY
    38 South Tees Acute Hospitals NHS Trust Middlesbrough, Cleveland England United Kingdom TS4 3BW
    39 Newcastle General Hospital Newcastle Upon Tyne England United Kingdom NE4 6BE
    40 Royal Victoria Infirmary Newcastle-upon-Tyne England United Kingdom NE1 4LP
    41 Mount Vernon Hospital Northwood England United Kingdom HA6 2RN
    42 Norfolk & Norwich Hospital Norwich England United Kingdom NR1 3SR
    43 Oxford Radcliffe Hospital Oxford England United Kingdom 0X3 7LJ
    44 Portsmouth Hospitals NHS Trust Portsmouth England United Kingdom P03 6AD
    45 Children's Hospital - Sheffield Sheffield England United Kingdom S10 2TH
    46 Weston Park Hospital Sheffield England United Kingdom S1O 2SJ
    47 Royal South Hants Hospital Southampton England United Kingdom SO14 0YG
    48 Southampton General Hospital Southampton England United Kingdom SO16 6YD
    49 Royal Marsden Hospital Sutton England United Kingdom SM2 5PT
    50 Princess Royal Hospital Telford England United Kingdom TF6 6TF
    51 Walsall Manor Hospital Walsall England United Kingdom WS2 9PS
    52 Southend General Hospital Westcliff-On-Sea England United Kingdom
    53 Royal Belfast Hospital for Sick Children Belfast Northern Ireland United Kingdom BT12 6BE
    54 Aberdeen Royal Infirmary Aberdeen Scotland United Kingdom AB25 2ZN
    55 Ninewells Hospital and Medical School Dundee Scotland United Kingdom DD1 9SY
    56 Western General Hospital Edinburgh Scotland United Kingdom EH4 9NQ
    57 Royal Hospital for Sick Children Edinburgh Scotland United Kingdom
    58 Beatson Oncology Centre Glasgow Scotland United Kingdom G11 6NT
    59 Royal Infirmary Glasgow Scotland United Kingdom G4 0SF
    60 Ysbyty Gwynedd Bangor Wales United Kingdom
    61 Llandough Hospital Penarth Wales United Kingdom CF6 1XX
    62 Royal Preston Hospital Preston United Kingdom PR2 9HT

    Sponsors and Collaborators

    • Medical Research Council

    Investigators

    • Study Chair: Peter G. Harper, MD, St. Thomas' Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00003175
    Other Study ID Numbers:
    • CDR0000065985
    • MRC-BA10
    • EU-97029
    First Posted:
    Apr 30, 2004
    Last Update Posted:
    Dec 4, 2013
    Last Verified:
    Feb 1, 2010

    Study Results

    No Results Posted as of Dec 4, 2013